<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2636">Amifostine</z:chebi>, a phosphorylated <z:chebi fb="0" ids="29256">thiol</z:chebi>-<z:chebi fb="39" ids="32952">amine</z:chebi>, is known as a cytoprotective agent especially for <z:chebi fb="2" ids="27899">cisplatin</z:chebi> containing chemotherapies </plain></SENT>
<SENT sid="1" pm="."><plain>Apart from the cytoprotective role, <z:chebi fb="0" ids="2636">Amifostine</z:chebi> could also be used in the treatment of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> such as <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), as a treatment option or for potentiating the effects of cytotoxic agents </plain></SENT>
<SENT sid="2" pm="."><plain>We tried to use <z:chebi fb="0" ids="2636">Amifostine</z:chebi> in a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, which did not respond to conventional cytotoxic chemotherapy and aimed to publish the results </plain></SENT>
<SENT sid="3" pm="."><plain>The patient was a 77-year-old male patient, he was diagnosed as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> by peripheral blood smear and bone marrow <z:hpo ids='HP_0002835'>aspiration</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment commenced with low dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (Ara-C) but the therapy should have ceased due to patient intolerance </plain></SENT>
<SENT sid="5" pm="."><plain>The patient refused further therapy and he was offered to have <z:chebi fb="0" ids="2636">Amifostine</z:chebi> treatment </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="2636">Amifostine</z:chebi> was administered 200 mg/m2 three times a week, with ciprofloxacin, pentoxifyllin and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Dramatic response was obtained after 8 weeks of administration </plain></SENT>
<SENT sid="8" pm="."><plain>Blast rate was reduced from 35 to 7% in bone marrow <z:hpo ids='HP_0002835'>aspiration</z:hpo>; <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> was restored to <z:mpath ids='MPATH_458'>normal</z:mpath> levels </plain></SENT>
<SENT sid="9" pm="."><plain>This remission was maintained through 8 more weeks </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="2636">Amifostine</z:chebi> treatment was restarted after he relapsed but this time he did not respond to the treatment and died of <z:hpo ids='HP_0002239'>gastrointestinal bleeding</z:hpo> on the 8th week of treatment </plain></SENT>
</text></document>